Literature DB >> 26941019

Lipoprotein(a) Levels Are Associated With Subclinical Calcific Aortic Valve Disease in White and Black Individuals: The Multi-Ethnic Study of Atherosclerosis.

Jing Cao1, Brian T Steffen1, Matthew Budoff1, Wendy S Post1, George Thanassoulis1, Bryan Kestenbaum1, Joseph P McConnell1, Russell Warnick1, Weihua Guan1, Michael Y Tsai2.   

Abstract

OBJECTIVE: Lipoprotein(a) [Lp(a)] is a risk factor for calcific aortic valve disease (CAVD) but has not been evaluated across multiple races/ethnicities. This study aimed to determine whether Lp(a) cutoff values used in clinical laboratories to assess risk of cardiovascular disease identify subclinical CAVD and its severity and whether significant relations are observed across race/ethnicity. APPROACH AND
RESULTS: Lp(a) concentrations were measured using a turbidimetric immunoassay, and subclinical CAVD was measured by quantifying aortic valve calcification (AVC) through computed tomographic scanning in 4678 participants of the Multi-Ethnic Study of Atherosclerosis. Relative risk and ordered logistic regression analysis determined cross-sectional associations of Lp(a) with AVC and its severity, respectively. The conventional 30 mg/dL Lp(a) clinical cutoff was associated with AVC in white (relative risk: 1.56; confidence interval: 1.24-1.96) and was borderline significant (P=0.059) in black study participants (relative risk: 1.55; confidence interval: 0.98-2.44). Whites with levels ≥50 mg/dL also showed higher prevalence of AVC (relative risk: 1.72; confidence interval: 1.36-2.17) than those below this level. Significant associations were observed between Lp(a) and degree of AVC in both white and black individuals. The presence of existing coronary artery calcification did not affect these associations of Lp(a) and CAVD. There were no significant findings in Hispanics or Chinese.
CONCLUSIONS: Lp(a) cutoff values that are currently used to assess cardiovascular risk seem to be applicable to CAVD, but our results suggest race/ethnicity may be important in cutoff selection. Further studies are warranted to determine whether race/ethnicity influences Lp(a) and risk of CAVD incidence and its progression.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  aortic valve, calcification of; atherosclerosis; immunoassay; prevalence; risk factor

Mesh:

Substances:

Year:  2016        PMID: 26941019      PMCID: PMC4850093          DOI: 10.1161/ATVBAHA.115.306683

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  38 in total

1.  Genome-wide linkage mapping for valve calcification susceptibility loci in hypertensive sibships: the Hypertension Genetic Epidemiology Network Study.

Authors:  Jonathan N Bella; Weihong Tang; Aldi Kraja; Dabeeru C Rao; Steven C Hunt; Michael B Miller; Vittorio Palmieri; Mary J Roman; Dalane W Kitzman; Albert Oberman; Richard B Devereux; Donna K Arnett
Journal:  Hypertension       Date:  2007-01-15       Impact factor: 10.190

2.  Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans.

Authors:  S M Marcovina; J J Albers; E Wijsman; Z Zhang; N H Chapman; H Kennedy
Journal:  J Lipid Res       Date:  1996-12       Impact factor: 5.922

3.  Patients with echocardiographic aortic valve calcium or mitral annular calcium have an increased prevalence of moderate or severe coronary artery calcium diagnosed by cardiac computed tomography.

Authors:  Sarah Kaplan; Wilbert S Aronow; Hoang Lai; Hajir Dilmanian; Albert J Deluca; Melvin B Weiss; Robert N Belkin
Journal:  Int J Angiol       Date:  2007

Review 4.  Lipoprotein(a) as a therapeutic target in cardiovascular disease.

Authors:  Marlys Koschinsky; Michael Boffa
Journal:  Expert Opin Ther Targets       Date:  2014-05-22       Impact factor: 6.902

5.  Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a).

Authors:  S M Marcovina; J J Albers; A M Scanu; H Kennedy; F Giaculli; K Berg; R Couderc; F Dati; N Rifai; I Sakurabayashi; J R Tate; A Steinmetz
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

Review 6.  Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease.

Authors:  Katherine E Yutzey; Linda L Demer; Simon C Body; Gordon S Huggins; Dwight A Towler; Cecilia M Giachelli; Marion A Hofmann-Bowman; Douglas P Mortlock; Melissa B Rogers; Mehran M Sadeghi; Elena Aikawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-04       Impact factor: 8.311

7.  Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study.

Authors:  Rudy Guerra; Zhaoxia Yu; Santica Marcovina; Ronald Peshock; Jonathan C Cohen; Helen H Hobbs
Journal:  Circulation       Date:  2005-03-21       Impact factor: 29.690

8.  Lack of association of lipoprotein(a) levels with coronary calcium deposits in asymptomatic postmenopausal women.

Authors:  M Nishino; M J Malloy; J Naya-Vigne; J Russell; J P Kane; R F Redberg
Journal:  J Am Coll Cardiol       Date:  2000-02       Impact factor: 24.094

9.  The prevalence and severity of coronary artery calcification on coronary artery computed tomography in black and white subjects.

Authors:  Timothy C Lee; Patrick G O'Malley; Irwin Feuerstein; Allen J Taylor
Journal:  J Am Coll Cardiol       Date:  2003-01-01       Impact factor: 24.094

10.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Authors:  Sotirios Tsimikas; Nicholas J Viney; Steven G Hughes; Walter Singleton; Mark J Graham; Brenda F Baker; Jennifer L Burkey; Qingqing Yang; Santica M Marcovina; Richard S Geary; Rosanne M Crooke; Joseph L Witztum
Journal:  Lancet       Date:  2015-07-22       Impact factor: 79.321

View more
  27 in total

1.  Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options.

Authors:  Andreja Rehberger Likozar; Mark Zavrtanik; Miran Šebeštjen
Journal:  Ann Med       Date:  2020-06-08       Impact factor: 4.709

2.  Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort).

Authors:  Archna Bajaj; Scott M Damrauer; Amanda H Anderson; Dawei Xie; Matthew J Budoff; Alan S Go; Jiang He; James P Lash; Akinlolu Ojo; Wendy S Post; Mahboob Rahman; Muredach P Reilly; Danish Saleheen; Raymond R Townsend; Jinbo Chen; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-08-24       Impact factor: 8.311

3.  Race-Based Differences in Lipoprotein(a)-Associated Risk of Carotid Atherosclerosis.

Authors:  Brian T Steffen; George Thanassoulis; Daniel Duprez; James H Stein; Amy B Karger; Mathew C Tattersall; Joel D Kaufman; Weihua Guan; Michael Y Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

Review 4.  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.

Authors:  Adam N Berman; Ron Blankstein
Journal:  Curr Cardiol Rep       Date:  2019-08-05       Impact factor: 2.931

5.  Calcification in atherosclerotic lesions.

Authors:  Hong Lu; Mary Sheppard; Alan Daugherty
Journal:  Curr Opin Lipidol       Date:  2016-10       Impact factor: 4.776

6.  Lp(a) [Lipoprotein(a)]-Related Risk of Heart Failure Is Evident in Whites but Not in Other Racial/Ethnic Groups.

Authors:  Brian T Steffen; Daniel Duprez; Alain G Bertoni; Weihua Guan; Michael Y Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-10       Impact factor: 8.311

7.  Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.

Authors:  Renata J M Engler; Emily Brede; Todd Villines; Marina N Vernalis
Journal:  Fed Pract       Date:  2019-11

8.  Risk factors for degenerative aortic valve disease in India: A case control study.

Authors:  D S Chadha; S K Malani; P Bharadwaj; G Karthikeyan; P K Hasija
Journal:  Med J Armed Forces India       Date:  2017-04-18

9.  Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic aorta: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Parveen K Garg; Weihua Guan; Amy B Karger; Brian T Steffen; Matthew Budoff; Michael Y Tsai
Journal:  J Cardiovasc Comput Tomogr       Date:  2020-06-21

10.  Lp(a) (Lipoprotein [a]) and Risk for Incident Atrial Fibrillation: Multi-Ethnic Study of Atherosclerosis.

Authors:  Parveen K Garg; Weihua Guan; Amy B Karger; Brian T Steffen; Wesley O'Neal; Susan R Heckbert; Erin D Michos; Michael Y Tsai
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.